187
Participants
Start Date
January 31, 2015
Primary Completion Date
May 11, 2022
Study Completion Date
May 11, 2022
TLPLDC
Autologous tumor lysate, particle-loaded dendritic cell vaccine
Placebo
Laura and Isaac Permutter Cancer Center @ NYU Langone, New York
Thomas Jefferson University, Philadelphia
St. Francis Hospital Cancer Center, Greenville
Northside Hospital Cancer Institute, Atlanta
Mount Sinai Cancer Research Program, Miami Beach
University of Alabama Birmingham (UAB) Comprehensive Cancer Center, Birmingham
The Ohio State University Comprehensive Cancer Center, Columbus
University of Cincinnati Cancer Institute, Cincinnati
Memorial Hospital of South Bend, South Bend
Mayo Clinic, Rochester, Rochester
Northwestern Memorial Hospital, Chicago
Huntsman Cancer Institute/The University of Utah, Salt Lake City
Mayo Clinic - Cancer Clinical Research Office, Phoenix
The University of Arizona Cancer Center, Tucson
New Mexico Cancer Care Alliance, Albuquerque
The Angeles Clinic and Research Institute A Cedars-Sinai Affiliate, Los Angeles
John Wayne Cancer Institute, Santa Monica
Providence Regional Medical Center Everett, Everett
Lead Sponsor
Collaborators (1)
LumaBridge
INDUSTRY
Elios Therapeutics, LLC
INDUSTRY